Mywy (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

Drospirenone/Ethinylestradiol, the active ingredients in Mywy, are a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus, and also helps regulate menstrual cycles.

GNH USA supplies Mywy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable logistics for global distribution. All batches undergo thorough independent quality testing before release.

Mywy, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle to prevent pregnancy. - Contraception: prevents pregnancy in women of childbearing potential by suppressing ovulation. - Menstrual cycle regulation: provides more predictable bleeding patterns and reduces menstrual flow. - Acne management: decreases androgen‑related acne lesions in women. - Dysmenorrhea relief: reduces painful menstrual cramps associated with ovulatory cycles.

Mywy may cause a range of adverse reactions, which are classified by frequency and severity. Common Side Effects: - Nausea - Breast tenderness - Headache Serious or Rare Side Effects: - Venous thromboembolism - Arterial thrombosis (stroke or myocardial infarction) - Severe allergic reaction (anaphylaxis)

When prescribing Mywy, clinicians should consider several safety measures. - Contraindicated in pregnancy: do not use during pregnancy. - Avoid smoking over age 35: increased risk of cardiovascular events. - Assess personal or family history of thromboembolism: evaluate risk before prescribing. - Monitor blood pressure regularly: combined oral contraceptives may elevate blood pressure. - Store at room temperature: keep in the original pack, protect from moisture.

Mywy can interact with other medicines, requiring careful assessment. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce contraceptive efficacy. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase hormone levels and risk of side effects. - Protease inhibitors (e.g., ritonavir): may lower effectiveness of hormonal contraception. Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin, phenobarbital): may modestly decrease contraceptive effect. - St. John’s wort: herbal inducer that can reduce hormone levels. - Selective serotonin reuptake inhibitors (SSRIs): may alter hormone metabolism, monitor for breakthrough bleeding.